Diarrhea on Foundayo™

Table 1 and its comparison group

The safety table pools Trial 1, in adults with obesity or overweight without diabetes, and Trial 2, in adults with type 2 diabetes, each lasting 72 weeks ^[1]. About 31% of the pooled population had type 2 diabetes. Every reaction in the table occurred in at least 5% of treated adults and more often than on placebo ^[1].

The US label covers weight management only, not the treatment of type 2 diabetes ^[1]. In Europe, a positive opinion of 15 October 2026 covers weight management and type 2 diabetes and lists diarrhoea with nausea and vomiting as the most frequent side effects, but with no EMA product information yet there is no European frequency band ^[3]. Health Canada’s drug database has no Foundayo™ or orforglipron entry ^[4].

The placebo figure changes the picture

Placebo diarrhea was 11%, the highest placebo rate for any reaction in Table 1, slightly above placebo nausea at 10% ^[1]. Over 72 weeks, a fair amount of diarrhea turns up whatever the treatment, and the placebo arm shows how much. Against that background, Foundayo™ roughly doubled the rate rather than multiplying it many times, as happened with vomiting.

The second notable feature is how flat the numbers are. The step from 5.5 mg to 17.2 mg, a more than threefold increase in dose, moved diarrhea by only four percentage points ^[1]. In this pool, the dose mattered much less for diarrhea than for vomiting or nausea.

Two weight trials, two placebo baselines

The label pool hides a difference that the trial registry shows. ClinicalTrials.gov reports each ATTAIN trial separately, using the investigational doses of 6, 12 and 36 mg that the label presents as Foundayo™ 5.5, 9 and 17.2 mg ^[1][5][6]. Both entries list only non-serious events reported by at least 5% of a group ^[5][6].

What the split shows

Placebo diarrhea was about one and a half times as common in ATTAIN-2 as in ATTAIN-1, while the orforglipron groups landed in a broadly similar range in both trials ^[5][6]. As a result, the gap between tablet and placebo was narrower in the diabetes trial. The registry entries do not say why the placebo arms differed, and this page does not guess.

Gastroenteritis, which NIDDK describes in its viral form as an infection of the intestines ^[9], was recorded under its own name in ATTAIN-1 and is not counted in the diarrhoea row ^[5]. It was somewhat more common on orforglipron than on placebo, but the registry does not say how cases were confirmed. ATTAIN-2 does not list it, which means only that no group reached 5% ^[6].

ACHIEVE-2 compared orforglipron with dapagliflozin, a diabetes tablet from another class, in 962 adults with type 2 diabetes already taking metformin ^[8]. It was open label, with only the orforglipron dose kept hidden, so participants knew which medicine they were on ^[8]. Diarrhoea was three to four times as common on orforglipron as on dapagliflozin ^[7], and stomach and bowel events overall affected 46% to 54% against 12% ^[8]. Knowing the treatment can colour what people report, and the US label does not cover type 2 diabetes ^[1].

Most likely during the dose steps

The label names diarrhea, nausea and vomiting as the reactions that were more frequent during escalation and then declined ^[1]. That escalation is slow by design. Section 2.1 begins at 0.8 mg daily and waits at least 30 days before each increase, explicitly to lower the risk of stomach and bowel reactions ^[1].

In practice, that gives a clear set of dates to watch: the first weeks on the tablet and the weeks after each new strength.

Diarrhea, fluids and the kidneys

Section 5.4 explains that acute kidney injury, in some cases needing hemodialysis, has been reported with GLP-1 receptor agonists and with Foundayo™ ^[1]. Most of those people had stomach reactions that led to dehydration, with diarrhea named alongside nausea and vomiting. In the pooled trials, acute kidney injury was reported in 0.2% on Foundayo™ against 0.05% on placebo ^[1].

The label asks prescribers to monitor kidney function when someone reports reactions that could lead to fluid loss, particularly at the start and during dose increases, and section 17 asks patients to guard against fluid depletion and report persistent diarrhea promptly ^[1]. The Medication Guide puts it in everyday terms: keep drinking to lower the chance of dehydration, and do not wait to tell your provider when nausea, vomiting or diarrhea persists ^[2]. Section 8.7 adds that kidney impairment on its own does not call for a dose change; the concern is the fluid lost, not the kidneys in isolation ^[1].

Why orforglipron may loosen stools

• What the label supports: diarrhea belongs to a cluster of stomach and bowel reactions that were more common on treatment, most frequent during escalation and less frequent later ^[1]. The label also describes slower stomach emptying, largest after the first dose and shrinking with time ^[1], but it does not name a mechanism for diarrhea.
• Not measured: none of the sources used here studied how orforglipron affects bowel transit, bile or gut bacteria. Such explanations exist for GLP-1 medicines generally but are untested for this tablet.
• General background: NIDDK names medicine side effects among the most common causes of short-term diarrhea, with viral gastroenteritis and food poisoning ^[9], so the tablet is a reasonable suspect but not the only one.

Other causes to keep in mind

NIDDK separates short-term diarrhea from diarrhea that lasts ^[9]:

• Short-term: viral gastroenteritis such as norovirus, food poisoning, travelers’ diarrhea, antibiotics, antacids containing magnesium, and sugar alcohols such as sorbitol in some liquid medicines.
• Lasting: allergies to foods such as cow’s milk, soy or eggs, intolerance to lactose, fructose or sucrose, and sugar-free sweets and gum.
• Digestive conditions: coeliac disease, Crohn’s disease, ulcerative colitis, pancreas problems, small intestinal bacterial overgrowth and diabetes-related nerve damage (autonomic neuropathy).
• Others: irritable bowel syndrome, past abdominal or stomach surgery, and long courses of antibiotics, which raise the chance of a C. difficile infection.

Fluids, food and pharmacy remedies in NIH guidance

NIDDK says most short-term diarrhea is treated by staying hydrated: water plus liquids that carry electrolytes, such as broths, sports drinks or oral rehydration solutions ^[10]. It asks older adults and people with diabetes or kidney disease to check with their doctor before using rehydration solutions ^[10]. MedlinePlus adds that small sips or ice chips can help when liquids are hard to keep down, and that sugary and caffeinated drinks are best avoided ^[12].

On food, NIDDK suggests returning to a usual diet once appetite comes back and, while diarrhea lasts, steering clear of alcohol, caffeine, fatty or fried foods, foods heavy in simple sugars such as fructose and lactose, and sugar alcohols ^[10][11]. For diarrhea that keeps coming back, it suggests a food and symptom journal to take to your doctor ^[11].

NIDDK says loperamide and bismuth subsalicylate can usually treat short-term diarrhea in adults, but not with bloody stools or fever, and that a doctor should be seen if diarrhea worsens or lasts beyond two days on them ^[10]. The Foundayo™ label does not mention either product. It does say the tablet slows stomach emptying and may change how other oral medicines are absorbed ^[1], so a pharmacist is the right person to check an over-the-counter remedy with.

What the documents leave unanswered

• How long a typical episode lasted in the trials, or on how many days people had diarrhea ^[1].
• Why placebo diarrhea was higher in the diabetes trial than in the trial without diabetes ^[5][6].
• Whether diarrhea returns when escalation restarts after a break; the label begins again at a lower strength after seven or more missed doses in a row but gives no figures for that situation ^[1].

Foundayo™ is a trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.

When to get help